TARRYTOWN, N.Y., Jan. 28, 2014 (GLOBE NEWSWIRE) -- Progenics Pharmaceuticals, Inc. (Nasdaq:PGNX), an oncology company focused on the development of innovative approaches to targeting and treating prostate cancer, will webcast a discussion of phase 2 data from two of its PSMA targeting late stage prostate cancer compounds. The discussion will cover 1404, its prostate cancer imaging agent, and PSMA ADC, its antibody drug conjugate therapeutic agent. Speakers will include Mark R. Baker, CEO, Hagop Youssoufian, M.D., Executive Vice President, Research and Development and Robert J. Israel, M.D., Executive Vice President, Medical Affairs.
Help employers find you! Check out all the jobs and post your resume.
